Log in with your email address username.

×

Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] WHO recommendations for multidrug-resistant tuberculosis

Giovanni Sotgiu and colleagues1 (June 18, p 2486) described the choices facing national tuberculosis programmes in implementing the 2016 WHO recommendations for drug-resistant tuberculosis.2 However, they might be being unduly pessimistic about the shortened treatment regimen (9–12 months). Successful implementation of this regimen, in settings from Somalia to India, shows the potential benefit for some patients with multidrug-resistant (MDR) tuberculosis.3

email